Table of Content

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Rising Global Geriatric Population
4.2.2. Rising Prevalence of Communicable and Non-communicable Diseases
4.2.3. Technological Advancements in Molecular Diagnostics
4.2.4. Rising Healthcare Expenditure
4.3. Restraints
4.3.1. Unfavorable Regulatory Framework
4.3.2. High Costs of Molecular Diagnostic Tests
4.4. Opportunities
4.4.1. Growing Scope in Emerging Economies
4.4.2. Increasing Focus on Companion Diagnostics
4.4.3. Rising Popularity of Direct-to-Consumer (DTC) Genetic Testing
4.5. Challenges
4.5.1. Shortage of Skilled Professionals
4.6. Trends
4.6.1. Integration of Artificial Intelligence and Machine Learning
4.7. The Impact of COVID-19 on the Global Molecular Diagnostics Market

5. Pricing Analysis

6. Global Molecular Diagnostics Market: Regulatory Analysis
6.1. North America
6.1.1. U.S.
6.1.2. Canada
6.2. Europe
6.3. Asia-Pacific
6.4. Latin America
6.5. Middle East & Africa

7. Global Molecular Diagnostics Market, by Product & Service
7.1. Introduction
7.2. Kits & Reagents
7.3. Instruments
7.4. Software & Services

8. Global Molecular Diagnostics Market, by Test Type
8.1. Introduction
8.2. Laboratory Tests
8.3. Point-of-Care (PoC) Tests

9. Global Molecular Diagnostics Market, by Technology
9.1. Introduction
9.2. Polymerase Chain Reaction (PCR)
9.3. In Situ Hybridization (ISH)
9.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
9.5. Microarrays
9.6. Mass Spectrometry
9.7. Sequencing
9.8. Other Technologies

10. Global Molecular Diagnostics Market, by Application
10.1. Introduction
10.2. Infectious Diseases
10.2.1. COVID-19
10.2.2. Hepatitis
10.2.3. HIV
10.2.4. Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
10.2.5. Human papillomavirus (HPV)
10.2.6. Tuberculosis
10.2.7. Influenza
10.2.8. Healthcare-associated Infections (HAIs)
10.2.9. Other Infectious Diseases
10.3. Oncology
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Lung Cancer
10.3.4. Prostate Cancer
10.3.5. Lymphoma
10.3.6. Leukemia
10.3.7. Cervical Cancer
10.3.8. Other Cancer Types
10.4. Genetic Testing
10.5. Neurological Diseases
10.6. Cardiovascular Diseases
10.7. Other Applications

11. Global Molecular Diagnostics Market, by End User
11.1. Introduction
11.2. Hospitals & Clinics
11.3. Diagnostic Laboratories
11.4. Academic & Research Institutes
11.5. Other End Users

12. Molecular Diagnostics Market, by Geography
12.1. Introduction
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.3. Europe
12.3.1. Germany
12.3.2. France
12.3.3. U.K.
12.3.4. Italy
12.3.5. Spain
12.3.6. Rest of Europe
12.4. Asia-Pacific
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia
12.4.5. Rest of Asia-Pacific
12.5. Latin America
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Middle East & Africa

13. Competitive Landscape
13.1. Introduction
13.2. Key Growth Strategies
13.3. Competitive Benchmarking
13.3.1. Competitive Benchmarking, by Product
13.4. Market Share Analysis (2022)

14. Company Profiles
14.1. F. Hoffmann-La Roche Ltd
14.2. Hologic, Inc.
14.3. QIAGEN N.V.
14.4. Danaher Corporation
14.5. bioM?rieux S.A.
14.6. Becton, Dickinson and Company (BD)
14.7. Siemens Healthineers AG
14.8. DiaSorin S.p.A.
14.9. Abbott Laboratories
14.10. Thermo Fisher Scientific Inc.
14.11. Agilent Technologies, Inc.
14.12. Illumina, Inc.
14.13. Seegene, Inc.

15. Appendix
15.1. Questionnaire
15.2. Available Customization



List of Figures


Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Molecular Diagnostic Market Size, by Product & Service, 2022 VS. 2029 (USD Million)
Figure 8 Global Molecular Diagnostic Market Size, by Test Type, 2022 VS. 2029 (USD Million)
Figure 9 Global Molecular Diagnostic Market Size, by Technology, 2022 VS. 2029 (USD Million)
Figure 10 Global Molecular Diagnostic Market Size, by Application, 2022 VS. 2029 (USD Million)
Figure 11 Global Molecular Diagnostic Market Size, by End User, 2022 VS. 2029 (USD Million)
Figure 12 Molecular Diagnostic Market, by Geography
Figure 13 Market Dynamics
Figure 14 Population Aged 65 Years or Over, by Region, 2020 VS. 2030 (In Million)
Figure 15 Global Molecular Diagnostics Market Size, by Product & Service, 2023–2030 (USD Million)
Figure 16 Global Molecular Diagnostics Market Size, by Test Type, 2023–2030 (USD Million)
Figure 17 Global Molecular Diagnostics Market Size, by Technology, 2023–2030 (USD Million)
Figure 18 Global Molecular Diagnostics Market Size, by Application, 2023–2030 (USD Million)
Figure 19 New Cancer Cases, by Cancer Type, 2020
Figure 20 Global Molecular Diagnostics Market Size, by End User, 2023–2030 (USD Million)
Figure 21 U.S.: Home Healthcare Spending, 2017–2026 (USD Billion)
Figure 22 Global Molecular Diagnostics Market Size, by Country/Region, 2023–2030 (USD Million)
Figure 23 North America: Molecular Diagnostics Market Snapshot
Figure 24 Canada: Number of Inpatient Admissions in Acute-Care Hospitals, 2016–2020 (Per 1,00,000 Population)
Figure 25 Europe: Molecular Diagnostics Market Snapshot
Figure 26 France: Population Aged 65 and Above (2016–2021)
Figure 27 U.K.: Number of People Diagnosed with Sexually Transmitted Infections, 2018–2020 (In Thousands)
Figure 28 Number of HIV Tests Performed in Catalonia, Spain (2014–2020)
Figure 29 Health Expenditure (2015–2020)
Figure 30 Asia-Pacific: Molecular Diagnostics Market Snapshot
Figure 31 Japan: Population Over 65 Years of Age (2017–2021)
Figure 32 Latin America: Molecular Diagnostics Market Snapshot
Figure 33 Latin America: Estimated Number of New Cancer Cases (2020–2030)
Figure 34 Key Growth Strategies Adopted by Leading Players, 2020?2022
Figure 35 Molecular Diagnostics Market: Competitive Benchmarking
Figure 36 Market Share Analysis: Molecular Diagnostics Industry (2022)
Figure 37 F. Hoffmann-La Roche Ltd: Financial Overview (2021)
Figure 38 Hologic, Inc.: Financial Overview (2021)
Figure 39 QIAGEN N.V.: Financial Overview (2021)
Figure 40 Danaher Corporation: Financial Overview (2021)
Figure 41 BioM?rieux S.A.: Financial Overview (2021)
Figure 42 Becton, Dickinson and Company: Financial Overview (2021)
Figure 43 Siemens Healthineers AG: Financial Overview (2021)
Figure 44 DiaSorin S.p.A.: Financial Overview (2021)
Figure 45 Abbott Laboratories: Financial Overview (2021)
Figure 46 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 47 Agilent Technologies, Inc.: Financial Overview (2021)
Figure 48 Illumina, Inc.: Financial Overview (2021)
Figure 49 Seegene, Inc.: Financial Overview (2021)